Active — Not RecruitingNot Applicable

RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

Australia6 participantsStarted 2021-12-14

Plain-language summary

This study aims to assess the clinical benefit of local ablative therapy (LAT) following initial standard first-line systemic treatment including the impact on survival, compared to continued standard first-line systemic treatment for oligometastatic colorectal cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. max of 3 lesions per organ except for the liver and lung
✓. max of 5 lesions in the lung
✓. no limitation to the number of liver lesions provided they are all amenable to LAT
✓. max of 3 involved organs including a lymph node station
✓. only one lymph node station involvement is allowed
✓. for patients with liver metastases, a quadruple phase contrast enhanced CT or MRI liver is required to fully stage the liver; this can be performed prior to or within 4 weeks of commencing first line systemic treatment
✓. staging FDG-PET scan is encouraged and can be performed prior to or within 4 weeks of commencing first line systemic treatment

What they're measuring

Progression free survival (PFS)

Timeframe: 12 Months from randomisation

Trial details

NCT IDNCT05862051

SponsorAustralasian Gastro-Intestinal Trials Group

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2025-12-31

View on ClinicalTrials.gov More Colorectal Cancer trials